Results 41 to 50 of about 2,710 (195)

Repositioning of inadvertent intralenticular ozurdex

open access: yesKerala Journal of Ophthalmology, 2020
With increasing availability and acceptability of intravitreal injections for various pathologies, the number of patients undergoing intravitreal injections has grown exponentially, hence increasing the risk of accidental trauma to the crystalline lens.
Piyush Kohli   +3 more
openaire   +1 more source

Radiation Macular Edema after Ru-106 Plaque Brachytherapy for Choroidal Melanoma Resolved by an Intravitreal Dexamethasone 0.7-mg Implant

open access: yesCase Reports in Ophthalmology, 2012
Purpose: To report the effective treatment of radiation macular edema following ruthenium-106 plaque brachytherapy for a choroidal melanoma with a dexamethasone 0.7-mg (Ozurdex®) intravitreal implant.
Andrea Russo   +12 more
doaj   +1 more source

Acute retinal necrosis following intravitreal dexamethasone (Ozurdex®) implant [PDF]

open access: yes, 2015
A 52-year-old woman undergoing azathioprine treatment for rheumatoid arthritis developed acute retinal necrosis a month after intravitreal dexamethasone (Ozurdex ®) implantation for posterior uveitis in the left eye.
Umit Yolcu (5762666)   +7 more
core   +1 more source

Efficacy and safety of intravitreal dexamethasone implant (Ozurdex®) in real-life practice

open access: yes, 2022
Millions of patients worldwide suffer from macular edema and associated loss of visual acuity. Luckily, the range of available treatments has widened over the past few years including the dexamethasone sustained-release implant (Ozurdex®) - a ...
Malcles, Ariane
core   +1 more source

Use of the dexamethasone implant as an adjunct in the treatment of Coats disease in a pediatric patient

open access: yesThe Pan-American Journal of Ophthalmology, 2022
To report the use of intravitreal dexamethasone implant and its short-term efficacy in a pediatric patient with Coats' disease. A 7-year-old patient was referred to the clinic because of decreased visual acuity in the right eye of 10-month duration. Best-
Salcedo Hugo Ricardo   +2 more
doaj   +1 more source

Dexamethasone implant (0.7 mg) in Indian patients with macular edema: Real-life scenario

open access: yesTaiwan Journal of Ophthalmology, 2018
Context: Role of Ozurdex in macular edema due to various posterior segment pathologies. AIM: The aim of this study is to report outcome of Ozurdex implant in macular edema (ME) secondary to various posterior segment pathologies. SETTINGS AND DESIGN: This
Manish Nagpal   +3 more
doaj   +1 more source

Intravitreal Dexamethasone Implant for the Treatment of Patient with Resistant to Anti-VEGF Diabetic Macular Edema

open access: yesОфтальмохирургия, 2020
Purpose. To evaluate the effectiveness of intravitreal injection of biodegradable intravitreal implant containing dexamethasone (Ozurdex) in patients with resistant diabetic macular edema (DME).Material and methods. The study was conducted of 24 patients
M. M. Bikbov   +4 more
doaj   +1 more source

To study the effect of intravitreal ozurdex implant in cases of retinal vein occlusion

open access: yesKerala Journal of Ophthalmology, 2022
Introduction: Retinal vein obstruction is one of the leading causes of severe vision impairment and blindness with treatment options mainly including laser, vascular endothelial growth factors, and steroids.
Shailender K Chaudhary   +4 more
doaj   +1 more source

Unusual fractured dexamethasone implant in the vitreous cavity

open access: yesJournal of Clinical Ophthalmology and Research
Ozurdex is an approved drug for managing vitritis. Raised intraocular pressure and cataract formation are known complications of Ozurdex implant; however, a fractured Ozurdex implant after injection is a rare entity.
Jui Telavane   +6 more
doaj   +1 more source

How Traumatic is Intravitreal Ozurdex Injection?

open access: yesOcular Immunology and Inflammation, 2021
This study intended to illustrate a rare case of pyogenic granuloma (PG) in retinal vein occlusion (RVO) patient after dexamethasone (DEX) implant therapy.A 58-year-old female who underwent DEX implant therapy a month ago due to RVO presented with a mass in her right eye.
Gulyesil F.f.   +9 more
openaire   +4 more sources

Home - About - Disclaimer - Privacy